Ratings ClouDr Group Limited

Equities

9955

KYG2216H1011

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-24 am EDT			5-day change	1st Jan Change
2.92 ^HKD	-2.99%		-12.84%	-57.37%

Apr. 15	ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services	MT
Mar. 22	ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The stock, which is currently worth 2024 to 0.29 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
CLOUDR GROUP LIMITED	-57.37%	219M	-
ABBOTT LABORATORIES	-5.56%	181B	C+
MEDTRONIC PLC	-0.11%	108B	C
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B	A
DEXCOM, INC.	+2.64%	50.65B	B-
CENCORA, INC.	+6.58%	43.66B	B-
HOYA CORPORATION	+4.91%	41.3B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B	B
TERUMO CORPORATION	+14.45%	25.03B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes